KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Net Income towards Common Stockholders: 2010-2025

Historic Net Income towards Common Stockholders for Pacira BioSciences (PCRX) over the last 16 years, with Sep 2025 value amounting to $5.4 million.

  • Pacira BioSciences' Net Income towards Common Stockholders rose 103.79% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.4 million, marking a year-over-year increase of 123.63%. This contributed to the annual value of -$99.6 million for FY2024, which is 337.30% down from last year.
  • Pacira BioSciences' Net Income towards Common Stockholders amounted to $5.4 million in Q3 2025, which was up 212.07% from -$4.8 million recorded in Q2 2025.
  • Pacira BioSciences' 5-year Net Income towards Common Stockholders high stood at $25.8 million for Q2 2023, and its period low was -$143.5 million during Q3 2024.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was $9.0 million (2024), whereas its average is -$4.7 million.
  • As far as peak fluctuations go, Pacira BioSciences' Net Income towards Common Stockholders skyrocketed by 1,666.81% in 2023, and later crashed by 1,421.29% in 2024.
  • Quarterly analysis of 5 years shows Pacira BioSciences' Net Income towards Common Stockholders stood at -$5.1 million in 2021, then slumped by 96.92% to -$10.1 million in 2022, then surged by 346.19% to $24.9 million in 2023, then slumped by 35.50% to $16.0 million in 2024, then surged by 103.79% to $5.4 million in 2025.
  • Its Net Income towards Common Stockholders was $5.4 million in Q3 2025, compared to -$4.8 million in Q2 2025 and $4.8 million in Q1 2025.